Blue Water Biotech Issues Letter to Shareholders
Blue Water Biotech, Inc. announces compliance with Nasdaq listing rule and strategic shift towards oncology. The company will focus on developing therapeutic, diagnostic, and service products in the field of oncology. The FDA-approved oral drug Entadfi® for benign prostatic hyperplasia will be launched in 2024. Previous acquisitions and vaccine programs will be de-prioritized as they do not align with the new focus.
Positive
Blue Water Biotech is back in compliance with Nasdaq listing rule 5250(c)(1).
The company will focus on building a foundation of oncology products to enhance shareholder value.
Entadfi®, an FDA-approved oral drug for benign prostatic hyperplasia, will be launched in 2024.
Negative
Previous acquisitions from WraSer and Xspire Pharma do not meet the company's requirements for creating greater shareholder value.
The company has de-prioritized its vaccine programs in favor of the new oncology focus.
10/30/2023 - 07:00 AM
CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer Dr. Neil Campbell.
Dear Shareholders,
As we close out October and the first month under my tenure, I want to take this opportunity to personally communicate with you while providing an update on the direction of Blue Water Biotech.
2023 has been an eventful year that has significantly influenced the Company’s progression in generating shareholder value. On October 24, 2023, Blue Water Biotech received a letter from Nasdaq informing the Company that it is back in compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1). This completes our outstanding obligations to the Nasdaq, and we will work diligently moving forward on this corporate requirement.
As a result of our internal assessments, the Company made a strategic decision to establish a new management team equipped with the necessary capabilities to swiftly advance our operations in the field of oncology.
As part of the shift in business strategy and to enhance shareholder value, the Company will focus its efforts on building a foundation of therapeutic, diagnostic, and service products in the field of oncology that will bolster and enrich the practice of medicine for clinicians.
With that in mind, a pivotal milestone for us is the impending launch of Entadfi® , an FDA-approved oral drug designed to treat benign prostatic hyperplasia (BPH). With the 2024 launch of Entadfi® it will become the inaugural therapeutic drug in our expanding portfolio of oncology therapeutics.
So where does this leave us with initiatives outside of our new focus? The Company’s previous activities in acquiring assets from WraSer, and Xspire Pharma, in early 2023 have been reassessed for strategic and tactical market considerations. It has been decided that these assets would not meet the Company’s requirements for creating greater shareholder value as we move into 2024.
Additionally, as a component of the asset purchase agreement involving WraSer and Xspire Pharma, the Company established commercial relationships intended for the marketing and sale of drug assets that are not aligned with our new oncology focus. Consequently, we have ceased this operation, recognizing its misalignment with our Company's evolving objective in the field of oncology.
Finally, the Company has established early stage preclinical and clinical programs in various vaccine technologies. These vaccine programs were targeting a wide number of diseases and conditions that would have consumed an enormous amount of Company resources. Considering the evolving market dynamics and post-pandemic challenges, we conducted a strategic and tactical assessment, leading us to conclude that the optimal path for the Company lies in a de-prioritization of the vaccine programs to focus our efforts on the expansion of our oncology offerings.
In summary, our business strategy shift aims to enhance shareholder value by establishing a strong foothold in both therapeutic and diagnostic aspects within the field of oncology. This approach involves actively cultivating key relationships and acquiring essential assets to lay the foundation in oncology and launch our initial stages of commercial revenue. With this, we eagerly anticipate building an accretive and focused company, providing leading-edge therapeutics, diagnostics, and services to clinicians, patients, and caregivers.
Thank you for your continued support of Blue Water Biotech.
Sincerely,
Dr. Neil Campbell
About Blue Water Biotech, Inc.
Blue Water Biotech, Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. The Company currently has Entadfi® , an oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Investor and Media Contact Information:
Russo Partners, LLC Nic.Johnson@russopartnersllc.com
What is the strategic shift announced by Blue Water Biotech, Inc.?
Blue Water Biotech is shifting its focus towards the field of oncology to enhance shareholder value.
What is the upcoming product launch by Blue Water Biotech, Inc.?
Blue Water Biotech will launch Entadfi®, an FDA-approved oral drug for benign prostatic hyperplasia, in 2024.
What will happen to the previous acquisitions made by Blue Water Biotech, Inc.?
The acquisitions from WraSer and Xspire Pharma have been reassessed and deemed not aligned with the company's new oncology focus.
What is the company's plan for its vaccine programs?
The vaccine programs will be de-prioritized as the company focuses on expanding its oncology offerings.
